San FRANCISCO
Biometric ring maker Oura postponed its Nasdaq listing Tuesday, citing market uncertainty. The company had drawn four times as many orders as shares available for a target raise of $2.2 billion.
The real issue: 73 percent of the proposed offering was earmarked for existing investors cashing out, not the company. That shareholder exit dynamic, combined with a pending sleep-accuracy class action lawsuit and $84.4 million in annual warranty costs, triggered investor pushback.
Oura's delay joins seven IPO postponements or withdrawals in Q3—up from four in Q2 and three in Q1. Recent pullbacks include nuclear power component maker Holtec Nuclear, materials company Amaero, and Bamboo Insurance.
"The fact that three prominent companies are doing this does indicate that it's not company-specific," said Jay Ritter, director of the IPO Initiative at the University of Florida's Warrington College of Business.
Macroeconomic headwinds are compounding the pressure. Bond yields sit at a 19-year high following resumed Federal Reserve rate hikes. Concerns about AI infrastructure buildout costs are also dampening appetite for new listings.
Year-to-date IPO proceeds stand at $146.9 billion across 110 deals (excluding SPACs)—down 30 percent from the same period last year. That aggregate figure masks the mega-deal distortion: SpaceX, SK Hynix, and Cerebras combined account for much of the total, yet all three are trading below their IPO prices.
Healthcare and industrials tied for the largest share of 2026 IPOs at 24 percent each. Technology ranked third at 18 percent. The Renaissance IPO ETF peaked in June following the SpaceX launch and has pulled back since.
